StockData
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. (EBS) stock

EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3074% below fair value
$5.61−0.20 (-3.44%)

Close on Nov 17, 2026Market cap $287.64MP/E –Yield –

Earnings

Emergent BioSolutions's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$110.00M
-52.4% on a year earlier
Adjusted Net Income (Loss) per Diluted Share, Q3 FY2026
-$0.36
$1.06 a year earlier
Latest guidance
Issued
Nov 2, 2026 · 6 items

Quarterly results

Revenue and earnings per share from each of Emergent BioSolutions's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 2, 2026after the close$110.00M-52.4%-$0.64-$0.36Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026after the close$234.30M+66.3%-$3.49$0.60Release
Q1 FY2026ended Mar 31, 2026Apr 30, 2026after the close$156.10M-29.7%$0.07$0.21Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026after the close$148.70M-23.6%-$1.04-$0.43Release
Q3 FY2025ended Sep 30, 2025Oct 29, 2025after the close$231.10M-21.3%$0.91$1.06Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025after the close$140.90M-44.7%-$0.22$0.16Release
Q1 FY2025ended Mar 31, 2025May 7, 2025after the close$222.20M-26.0%$1.19$0.71Release
Q4 FY2024ended Dec 31, 2024Mar 3, 2025after the close$194.70M-29.6%-$0.58$0.05Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024after the close$293.80M+8.6%$2.06$1.37Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024after the close$254.70M-24.6%-$5.38-$2.32Release
Q1 FY2024ended Mar 31, 2024May 1, 2024after the close$300.40M+82.0%$0.17$0.59Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Emergent BioSolutions's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Total revenuesFY2026$600.00M – $645.00M–NewNov 2, 2026
Total revenuesFY2026$645.00M – $675.00M$720.00M – $760.00MLoweredAug 5, 2026
Adjusted gross margin %non-GAAPFY202645% – 47%–NewNov 2, 2026
Adjusted gross margin %non-GAAPFY202642% – 44%45% – 47%LoweredAug 5, 2026
Gross margin %GAAPFY202632% – 35%35% – 38%LoweredAug 5, 2026
Adjusted EBITDAnon-GAAPFY2026$110.00M – $140.00M–NewNov 2, 2026
Adjusted EBITDAnon-GAAPFY2026$130.00M – $150.00M$155.00M – $175.00MLoweredAug 5, 2026
CapexFY2026$16.00M–NewNov 2, 2026
CapexFY2026$17.00M$17.00MReaffirmedAug 5, 2026
Adjusted gross marginnon-GAAPFY2026$308.00M – $341.00M–NewFeb 26, 2026
Adjusted net incomenon-GAAPFY2026$10.00M – $30.00M$45.00M – $65.00MLoweredAug 5, 2026
Adjusted net income (loss)non-GAAPFY2026-$10.00M – $20.00M–NewNov 2, 2026
Depreciation & amortizationFY2026$82.00M–RaisedAug 5, 2026
Gross marginGAAPFY2026$240.00M – $273.00M–NewFeb 26, 2026
Interest expenseFY2026$40.00M–NewAug 5, 2026
Net lossGAAPFY2026-$255.00M – -$225.00M–NewNov 2, 2026
Net lossGAAPFY2026-$245.00M – -$225.00M–LoweredAug 5, 2026
R&DFY20266%–NewAug 5, 2026
SG&AFY202627% – 28%–RaisedAug 5, 2026
Stock-based compensation expenseFY2026$19.00M–LoweredAug 5, 2026
Weighted avg. fully diluted share countFY202652–NewAug 5, 2026

Guidance vs results

The last range Emergent BioSolutions gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q3 FY2026Revenue$110.00M – $130.00M$110.00MWithin range
Q2 FY2026Revenue$170.00M – $185.00M$234.30MAbove range
Q1 FY2026Revenue$135.00M – $155.00M$156.10MAbove range
FY2025Revenue$775.00M – $835.00M$742.90MΣ4QBelow range
Q3 FY2025Revenue$180.00M – $210.00M$231.10MAbove range
Q2 FY2025Revenue$95.00M – $120.00M$140.90MAbove range
Q1 FY2025Revenue$200.00M – $240.00M$222.20MWithin range
Q3 FY2024Revenue$265.00M – $315.00M$293.80MWithin range
Q2 FY2024Revenue$160.00M – $210.00M$254.70MAbove range
Q1 FY2024Revenue$200.00M – $250.00M$300.40MAbove range
Q3 FY2023Revenue$210.00M – $250.00M$270.50MAbove range
Q2 FY2023Revenue$210.00M – $230.00M$337.90MAbove range

Guidance history

Every forecast Emergent BioSolutions put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 2, 2026CapexFY2026$16.00MNew
Nov 2, 2026Adjusted EBITDAFY2026$110.00M – $140.00MNew
Nov 2, 2026Adjusted gross margin %FY202645% – 47%New
Nov 2, 2026Net lossFY2026-$255.00M – -$225.00MNew
Nov 2, 2026Adjusted net income (loss)FY2026-$10.00M – $20.00MNew
Nov 2, 2026Total revenuesFY2026$600.00M – $645.00MNew
Aug 5, 2026CapexFY2026$17.00MReaffirmed
Aug 5, 2026Adjusted EBITDAFY2026$130.00M – $150.00MLowered
Aug 5, 2026Gross margin %FY202632% – 35%Lowered
Aug 5, 2026Adjusted gross margin %FY202642% – 44%Lowered
Aug 5, 2026Net lossFY2026-$245.00M – -$225.00MLowered
Aug 5, 2026Weighted avg. fully diluted share countFY202652New
Aug 5, 2026R&DFY20266%New
Aug 5, 2026SG&AFY202627% – 28%Raised
Aug 5, 2026Interest expenseFY2026$40.00MNew
Aug 5, 2026Stock-based compensation expenseFY2026$19.00MLowered
Aug 5, 2026Depreciation & amortizationFY2026$82.00MRaised
Aug 5, 2026Adjusted net incomeFY2026$10.00M – $30.00MLowered
Aug 5, 2026Total revenuesFY2026$645.00M – $675.00MLowered
Aug 5, 2026Total revenuesQ3 FY2026$110.00M – $130.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Emergent BioSolutions filed with the SEC as exhibits to Form 8-K or 6-K

  1. News
  2. Results
  3. Results
  4. Update
  5. News
  6. Results
  7. Results
  8. Update
  9. Results
  10. Results
  11. Update
  12. Update
  13. Results
  14. Results
  15. Update

See a number that looks wrong?